Skip to main content

Table 7 Frequency and grade of adverse events of the 12 patients

From: A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment

Gradea I II III IV V
Adverse event
Local pain 3/12b 2/12    
Local swelling   1/12    
Fever 5/12 2/12    
Skin rash/itching/skin desquamation 3/12 2/12    
Myalgia 1/12     
Bilirubin 4/12 1/12 2/12 1/12  
GPT 9/12 2/12    
GOT 9/12 2/12 1/12   
Hemorrhage (UGIc)   1/12    
Diarrhea/Mucocitis 3/12 1/12 2/12   
Creatinine 1/12 1/12    
Allergy 1/12 1/12    
Anemia 1/12 1/12    
Short of breath 2/12     
Sweating 1/12     
Chillness 1/12     
Leg edema 1/12     
  1. aAdverse event was determined using CTCAE version 4.0
  2. b“3/12” indicates that 3 of 12 patients had at least one episode of a particular adverse event
  3. cUGI indicates upper gastrointestinal